The new Line Immunoassay technology for Lyme confirmation testing from Gold Standard Diagnostics Corp, Davis, Calif, gives clinical labs an FDA-cleared, improved option for serological confirmation testing for Lyme disease according to the Centers for Disease Control (CDC)-recommended two-step process.
Both the IgG and IgM line blots are substantially equivalent to traditional Western Blot technology, but offer advancements in usability and objectivity through use of Line Immunoassay technology, according to the company.
The LIA test strips offer enhancements such as improved sensitivity and specificity, consistent results, large lot sizes, easier handling, and automation options.
Nitrocellulose-backed and individually numbered strips make handling easy and foolproof.
Clear bands for each antigen, a serum control band, and a cutoff control band make it easy to interpret each sample result. Also, strips can be scanned and interpreted by the company’s software.
Ten IgG antigens match CDC requirements for testing for general infection as well as determination of the stage of infection. All three IgM proteins are included for early and disseminated Lyme disease diagnosis.
Strips are affixed in a booklet of durable materials allowing for easy handling. The numbering system makes working with the Lyme line blots simple, regardless of testing volume. The blots can be run manually or on a fully-automated processor/reader system.
[Source: Gold Standard Diagnostics]
